Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Recurrent/Metastatic Salivary Gland Carcinoma
NCT03132038Phase 2Completed
- Sponsor
- Unicancer
- Start
- Mar 2017
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in salivary gland carcinoma (SGC), sponsored by Unicancer. Primary endpoint: Non-progression rate at 6 months. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT03132038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132038.